Result of AGM

RNS Number : 0309Q

Redx Pharma plc

24 February 2016

 

AIM: REDX

 REDX PHARMA PLC

("Redx" or "the Company")

Result of AGM

Redx, the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.

For further information, please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Shore Capital (Nomad and Broker)	T: 020 7408 4090
Bidhi Bhoma/ Edward Mansfield/ Patrick Castle
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

RAGPGURWPUPQGPC